Takeda Pharmaceutical (TAK) Cash & Equivalents Growth (3y) (2020 - 2026)

Takeda Pharmaceutical (TAK) Cash & Equivalents Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - 29.96%
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 20.41%
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -2.73%
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.02%
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 3.22%
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 52.71%
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 36.93%
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 10.41%
10 Vireo Growth 10.51 Bn 10.36 Bn 59.30 Mn 137.05%

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.02%
Dec 31, 2025 -4.26%
Sep 30, 2025 -7.16%
Jun 30, 2025 -21.47%
Mar 31, 2025 -29.85%
Dec 31, 2024 -20.10%
Sep 30, 2024 1.41%
Jun 30, 2024 -4.77%
Mar 31, 2024 -30.31%
Dec 31, 2023 -30.89%
Sep 30, 2023 -28.17%
Jun 30, 2023 -25.05%
Mar 31, 2023 -11.69%
Sep 30, 2022 4.49%
Jun 30, 2022 -2.56%
Mar 31, 2022 4.66%
Dec 31, 2021 34.13%
Mar 31, 2021 49.77%
Dec 31, 2020 14.88%